Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.
Journal
Nature aging
ISSN: 2662-8465
Titre abrégé: Nat Aging
Pays: United States
ID NLM: 101773306
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
30
06
2023
accepted:
02
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
25
6
2024
Statut:
aheadofprint
Résumé
Adenoviral and mRNA vaccines encoding the viral spike (S) protein have been deployed globally to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older individuals are particularly vulnerable to severe infection, probably reflecting age-related changes in the immune system, which can also compromise vaccine efficacy. It is nonetheless unclear to what extent different vaccine platforms are impacted by immunosenescence. Here, we evaluated S protein-specific immune responses elicited by vaccination with two doses of BNT162b2 or ChAdOx1-S and subsequently boosted with a single dose of BNT162b2 or mRNA-1273, comparing age-stratified participants with no evidence of previous infection with SARS-CoV-2. We found that aging profoundly compromised S protein-specific IgG titers and further limited S protein-specific CD4
Identifiants
pubmed: 38918602
doi: 10.1038/s43587-024-00644-w
pii: 10.1038/s43587-024-00644-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : DH | National Institute for Health Research (NIHR)
ID : COV-LT2-0041
Investigateurs
Elena Barbieri
(E)
Tatiana Bernardi
(T)
Michela Boni
(M)
Linda Dall'Olio
(L)
Martina De Laurentis
(M)
Caterina Fiorini
(C)
Michele Fiorini
(M)
Maurizio Govoni
(M)
Margherita Neri
(M)
Fabio Palma
(F)
Franco Romagnoni
(F)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
pubmed: 34614326
doi: 10.1056/NEJMoa2114583
Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924–944 (2022).
pubmed: 35202601
pmcid: 8863502
doi: 10.1016/S0140-6736(22)00152-0
Andeweg, S. P. et al. Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals. Sci. Transl. Med. 15, eabn4338 (2023).
pubmed: 35862508
doi: 10.1126/scitranslmed.abn4338
Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393–1400 (2021).
pubmed: 34525275
doi: 10.1056/NEJMoa2114255
Tan, S. T. et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat. Med. 29, 358–365 (2023).
pubmed: 36593393
pmcid: 9974584
doi: 10.1038/s41591-022-02138-x
Maringer, Y. et al. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci. Immunol. 7, eadd3899 (2022).
pubmed: 36318037
pmcid: 9798886
doi: 10.1126/sciimmunol.add3899
Nicoli, F., Paudel, D. & Solis-Soto, M. T. Old and new coronaviruses in the elderly. Aging 13, 12295–12296 (2021).
pubmed: 33982672
pmcid: 8148481
doi: 10.18632/aging.203065
Nicoli, F. et al. Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity. Geroscience 42, 1015–1019 (2020).
pubmed: 32583231
pmcid: 7312114
doi: 10.1007/s11357-020-00217-w
Arregocés-Castillo, L. et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev. 3, e242–e252 (2022).
pubmed: 35340743
pmcid: 8937302
doi: 10.1016/S2666-7568(22)00035-6
Van Ewijk, C. E., Hazelhorst, E. I., Hahne, S. J. M. & Knol, M. J. COVID-19 outbreak in an elderly care home: very low vaccine effectiveness and late impact of booster vaccination campaign. Vaccine 40, 6664–6669 (2022).
pubmed: 36216647
pmcid: 9531647
doi: 10.1016/j.vaccine.2022.09.080
Nanishi, E., Levy, O. & Ozonoff, A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum. Vaccin. Immunother. 18, 2045857 (2022).
pubmed: 35240940
pmcid: 9196671
doi: 10.1080/21645515.2022.2045857
Bajči, M. P. et al. COVID-19 breakthrough infections among patients aged ≥65 years in Serbia: morbidity and mortality overview. Vaccines 10, 1818 (2022).
Ventura, M. I. et al. Vaccine breakthrough infections with SARS-CoV-2: why older adults need booster vaccinations. Public Health Pract. 4, 100307 (2022).
doi: 10.1016/j.puhip.2022.100307
Hazeldine, J. & Lord, J. M. Innate immunesenescence: underlying mechanisms and clinical relevance. Biogerontology 16, 187–201 (2015).
pubmed: 25009085
doi: 10.1007/s10522-014-9514-3
Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. & Riella, L. V. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. Front. Immunol. 11, 1748 (2020).
pubmed: 32849623
pmcid: 7427491
doi: 10.3389/fimmu.2020.01748
Gallerani, E. et al. Impaired priming of SARS-CoV-2-specific naive CD8
pubmed: 34326844
pmcid: 8315546
doi: 10.3389/fimmu.2021.693054
Proietto, D. et al. Ageing curtails the diversity and functionality of nascent CD8
Nicoli, F. et al. Altered basal lipid metabolism underlies the functional impairment of naive CD8
pubmed: 35031578
doi: 10.4049/jimmunol.2100194
Xiao, C. et al. Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults. Nat. Aging 3, 418–435 (2023).
pubmed: 37117789
pmcid: 10154213
doi: 10.1038/s43587-023-00379-0
Nicoli, F. et al. Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. EBioMedicine 76, 103852 (2022).
pubmed: 35114631
pmcid: 8818547
doi: 10.1016/j.ebiom.2022.103852
Zhang, H., Weyand, C. M., Goronzy, J. J. & Gustafson, C. E. Understanding T cell aging to improve anti-viral immunity. Curr. Opin. Virol. 51, 127–133 (2021).
pubmed: 34688983
pmcid: 8643327
doi: 10.1016/j.coviro.2021.09.017
Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 145, 1309–1321 (2020).
pubmed: 32386655
pmcid: 7198995
doi: 10.1016/j.jaci.2020.03.017
Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 28, 1072–1082 (2022).
pubmed: 35165453
pmcid: 9117148
doi: 10.1038/s41591-022-01721-6
Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417–422 (2021).
pubmed: 34192737
pmcid: 8373615
doi: 10.1038/s41586-021-03739-1
Tut, G. et al. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study. Lancet Healthy Longev. 3, e461–e469 (2022).
pubmed: 35813280
pmcid: 9252532
doi: 10.1016/S2666-7568(22)00118-0
Roukens, A. H. et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS ONE 6, e27753 (2011).
pubmed: 22163273
pmcid: 3233541
doi: 10.1371/journal.pone.0027753
Weinberger, B. et al. Impaired immune response to primary but not to booster vaccination against hepatitis B in older adults. Front. Immunol. 9, 1035 (2018).
pubmed: 29868000
pmcid: 5962691
doi: 10.3389/fimmu.2018.01035
Kim, D. K. et al. Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Ann. Intern. Med. 168, 210–220 (2018).
pubmed: 29404596
doi: 10.7326/M17-3439
Weinberger, B. Vaccines for the elderly: current use and future challenges. Immun. Ageing 15, 3 (2018).
pubmed: 29387135
pmcid: 5778733
doi: 10.1186/s12979-017-0107-2
Chivu-Economescu, M. et al. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19. J. Cell. Mol. Med. 26, 1293–1305 (2022).
pubmed: 35043552
pmcid: 8831971
doi: 10.1111/jcmm.17186
Newman, J. et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nat. Microbiol. 7, 1180–1188 (2022).
pubmed: 35836002
pmcid: 9352594
doi: 10.1038/s41564-022-01163-3
Agallou, M. et al. Antibody and T-cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2. J. Infect. Dis. 227, 353–363 (2023).
pubmed: 36259394
doi: 10.1093/infdis/jiac421
Brasu, N. et al. Memory CD8
pubmed: 36138186
doi: 10.1038/s41590-022-01313-z
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
pubmed: 34002089
doi: 10.1038/s41591-021-01377-8
Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398, 1407–1416 (2021).
pubmed: 34619098
pmcid: 8489881
doi: 10.1016/S0140-6736(21)02183-8
Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).
pubmed: 33516277
pmcid: 7826084
doi: 10.1016/j.celrep.2021.108728
Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434–2451 (2022).
pubmed: 35764089
pmcid: 9135677
doi: 10.1016/j.cell.2022.05.022
Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 27, 1530–1535 (2021).
pubmed: 34312554
pmcid: 8440177
doi: 10.1038/s41591-021-01464-w
Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir. Med. 9, 1255–1265 (2021).
pubmed: 34391547
pmcid: 8360702
doi: 10.1016/S2213-2600(21)00357-X
Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398, 2258–2276 (2021).
pubmed: 34863358
pmcid: 8639161
doi: 10.1016/S0140-6736(21)02717-3
Collier, A. Y. et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N. Engl. J. Med. 385, 2010–2012 (2021).
pubmed: 34648703
doi: 10.1056/NEJMc2115596
Guerrera, G. et al. BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci. Immunol. 6, eabl5344 (2021).
pubmed: 34726470
doi: 10.1126/sciimmunol.abl5344
Lau, J. J. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29, 348–357 (2023).
pubmed: 36652990
pmcid: 9941049
doi: 10.1038/s41591-023-02219-5
Lustig, Y. et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat. Immunol. 23, 940–946 (2022).
pubmed: 35534723
doi: 10.1038/s41590-022-01212-3
Wolszczak Biedrzycka, B., Bieńkowska, A., Smolińska-Fijołek, E., Biedrzycki, G. & Dorf, J. The influence of two priming doses of different anti-COVID-19 vaccines on the production of anti-SARS-CoV-2 antibodies after the administration of the Pfizer/BioNTech booster. Infect. Drug Resist. 15, 7811–7821 (2022).
pubmed: 36600955
pmcid: 9807069
doi: 10.2147/IDR.S390351
Atmar, R. L. et al. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med. 386, 1046–1057 (2022).
pubmed: 35081293
doi: 10.1056/NEJMoa2116414
Koutsakos, M. et al. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity 56, 879–892 (2023).
pubmed: 36958334
pmcid: 9970913
doi: 10.1016/j.immuni.2023.02.017
Terpos, E. et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am. J. Hematol. 96, E257–E259 (2021).
pubmed: 33837984
pmcid: 8250071
doi: 10.1002/ajh.26185
Müller, L. et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin. Infect. Dis. 73, 2065–2072 (2021).
pubmed: 33906236
doi: 10.1093/cid/ciab381
Palacios-Pedrero, M. Á. et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nat. Aging 2, 896–905 (2022).
pubmed: 37118289
pmcid: 10154205
doi: 10.1038/s43587-022-00292-y
Tut, G. et al. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes. Nat. Aging 3, 93–104 (2023).
pubmed: 37118525
pmcid: 10154221
doi: 10.1038/s43587-022-00328-3
Parry, H. et al. Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Rep. Med. 3, 100739 (2022).
pubmed: 36075216
pmcid: 9404227
doi: 10.1016/j.xcrm.2022.100739
Wang, Z. et al. Memory B cell development elicited by mRNA booster vaccinations in the elderly. J. Exp. Med. 220, e20230668 (2023).
Demaret, J. et al. Impaired functional T-cell response to SARS-CoV-2 after two doses of BNT162b2 mRNA vaccine in older people. Front. Immunol. 12, 778679 (2021).
pubmed: 34868051
pmcid: 8637126
doi: 10.3389/fimmu.2021.778679
Jo, N. et al. Impaired CD4
pubmed: 37118516
pmcid: 10154196
doi: 10.1038/s43587-022-00343-4
Breznik, J. A. et al. Cytomegalovirus seropositivity in older adults changes the T cell repertoire but does not prevent antibody or cellular responses to SARS-CoV-2 vaccination. J. Immunol. 209, 1892–1905 (2022).
pubmed: 36426948
pmcid: 9666329
doi: 10.4049/jimmunol.2200369
Vogel, E. et al. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. EBioMedicine 85, 104294 (2022).
pubmed: 36206622
pmcid: 9530590
doi: 10.1016/j.ebiom.2022.104294
Rosenberg, E. S. et al. Covid-19 vaccine effectiveness in New York State. N. Engl. J. Med. 386, 116–127 (2022).
pubmed: 34942067
doi: 10.1056/NEJMoa2116063
Price, D. A. et al. Avidity for antigen shapes clonal dominance in CD8
pubmed: 16287711
pmcid: 2212993
doi: 10.1084/jem.20051357
Nicoli, F. et al. The HIV-1 Tat protein affects human CD4
pubmed: 29280760
doi: 10.1097/QAD.0000000000001734